Praxis an der Oper
- Address
- Bismarckstr. 30, 10625 Berlin, Germany
Praxis an der Oper - Respiratory Medicine Research
Praxis an der Oper is a clinical research facility specializing in respiratory medicine with a particular focus on Chronic Obstructive Pulmonary Disease (COPD) management and treatment optimization. The center participates in advanced pharmaceutical research aimed at improving outcomes for patients with chronic respiratory conditions requiring complex therapeutic regimens.
- COPD exacerbation prevention strategies
- Advanced triple therapy optimization studies
- Novel add-on therapeutic interventions for maintenance COPD treatment
The research center demonstrates expertise in evaluating innovative drug delivery systems and assessing long-term efficacy outcomes in patients with established respiratory disease. Their involvement in sophisticated clinical trials examining the safety and effectiveness of emerging pharmaceutical agents positions them at the forefront of respiratory medicine research, particularly in studies designed to reduce disease exacerbations and improve quality of life for COPD patients on complex maintenance therapy protocols.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Chiesi Farmaceutici S.p.A.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Chiesi Farmaceutici S.p.A.3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Praxis an der Oper
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Tanimilast (CHF6001) as an Add-On to Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis | Chiesi Farmaceutici S.p.A. | Phase III | Not Recruiting | Jun 2021 | Jun 2025 |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Formoterol Fumarate Dihydrate | 2 | Unknown | 2024-07-04 | 2026-04-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.